Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Sponsor: University of Chicago
Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Official title: A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
Key Details
Gender
MALE
Age Range
70 Years - Any
Study Type
INTERVENTIONAL
Enrollment
155
Start Date
2026-06
Completion Date
2027-06
Last Updated
2025-10-01
Healthy Volunteers
No
Conditions
Interventions
LHRH Agonist Therapy Discontinuation
The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
Locations (2)
The University of Illinois at Chicago (UIC)
Chicago, Illinois, United States
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States